These drugs work, and they are very helpful for targeting obesity, but it's because they are so successful that they have some negative body composition effects
verify on Quartz formulary
Resistance training protocols Resistance training serves triple duty for autoimmune patients on tirzepatide: it preserves lean mass during weight loss, independently reduces inflammatory markers, and improves joint stability and function
N Engl J Med 2025;393:1796-1806 [9] Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial, December 2025: Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial | Eli Lilly and Company [10] Fourth High-level Meeting of the UN General Assembly on the prevention and control of NCDs and the promotion of mental health and wellbeing (HLM4), September 2025: [11] Thousands of patients from Scotlands poorest areas to benefit from landmark UK government-funded obesity study, November 2025: Thousands of patients from Scotlands poorest areas to benefit from landmark UK government-funded obesity study - GOV.UK [12] Non-Traditional Channels: The Compounded GLP-1 Market
Aside from that isolated distribution recall, the FDA has not issued a recall Victoza for safety reasons such as an undisclosed defect or imminent risk to patients
For example, Tesamorelin may help reduce deep belly fat (visceral fat) while preserving lean mass, and Tesofensine can suppress appetite and increase energy expenditure
